Top Page
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
(1858)
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) vs. iShares MSCI Hong Kong ETF (EWH)
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.05B | 805.86M | 1.21B | 1.20B | 1.11B | 937.69M |
| Gross Profit | 645.92M | 516.49M | 875.89M | 913.53M | 854.54M | 680.76M |
| EBITDA | 260.41M | 169.32M | 340.65M | 366.96M | 360.99M | 349.78M |
| Net Income | 255.34M | 124.99M | 277.82M | 307.72M | 322.36M | 283.37M |
Balance Sheet | ||||||
| Total Assets | 3.54B | 3.47B | 3.65B | 3.41B | 3.00B | 1.54B |
| Cash, Cash Equivalents and Short-Term Investments | 2.00B | 1.89B | 2.10B | 1.72B | 1.74B | 690.12M |
| Total Debt | 218.59K | 866.44K | 1.75M | 1.31M | 1.23M | 1.85M |
| Total Liabilities | 554.07M | 644.39M | 770.33M | 690.07M | 530.58M | 460.41M |
| Stockholders Equity | 2.98B | 2.82B | 2.88B | 2.72B | 2.47B | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | 125.96M | -51.07M | 478.47M | 16.10M | -34.62M | 236.68M |
| Operating Cash Flow | 191.78M | -1.90M | 511.71M | 41.01M | 164.79M | 260.68M |
| Investing Cash Flow | -176.67M | 55.84M | -81.56M | -762.61M | -190.35M | -21.54M |
| Financing Cash Flow | -66.40M | -183.14M | -121.33M | -59.04M | 1.07B | -11.88M |
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.13B | 15.57 | 8.59% | 2.76% | 13.59% | 6.31% | |
69 Neutral | HK$6.46B | 20.18 | 11.24% | 1.26% | 25.18% | 55.79% | |
69 Neutral | HK$9.56B | 20.24 | 8.69% | 1.88% | 14.56% | 61.60% | |
58 Neutral | HK$8.29B | 46.97 | 4.99% | 0.48% | 35.01% | 483.73% | |
57 Neutral | HK$7.43B | 104.49 | 1.98% | ― | 3.42% | -70.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.33B | -18.39 | -11.20% | ― | 29.25% | 9.02% |
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events
Beijing Chunlizhengda Medical Instruments Co., Ltd. expects a sharp jump in profitability for 2025, forecasting net profit attributable to shareholders of RMB244.99 million to RMB287.99 million, up about 96% to 130% year on year, and net profit excluding non-recurring items of RMB229.54 million to RMB269.54 million, up roughly 143% to 185%. The company attributes the projected surge in earnings to the growth potential released after its product lines were included in centralized procurement, steady progress in its international expansion, and improvements in operational management and resource allocation, which have supported sustained revenue growth and higher overall profitability, although the figures remain preliminary and unaudited.
The most recent analyst rating on (HK:1858) stock is a Buy with a HK$18.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. held an extraordinary general meeting (EGM) on 29 December 2025 in Beijing, convened by its board and chaired by chairman Shi Wenling, with all directors in attendance either in person or by telephone. The meeting, which complied with PRC law, Hong Kong Listing Rules and the company’s articles, adopted a combination of internet voting via the Shanghai Stock Exchange trading system for A shareholders and onsite poll voting, with its auditor Wuyige Certified Public Accountants LLP acting as scrutineer; out of 383,568,500 issued shares, 382,191,649 were eligible to vote after excluding treasury shares, and 229,835,580 voting shares were represented by 39 shareholders and proxies (38 A-share holders and one H-share holder), with no shareholders required to abstain or having indicated plans to vote against any resolutions.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced an extraordinary general meeting scheduled for December 29, 2025, to discuss significant changes in its corporate governance structure. The agenda includes the abolishment of the Supervisory Committee and amendments to the Articles of Association, Rules of Procedures of the General Meetings, and Board Meetings. These changes could impact the company’s operational framework and governance, potentially affecting its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has established a Remuneration and Assessment Committee to enhance its corporate governance framework. This committee is tasked with developing and reviewing remuneration policies and evaluation standards for directors and senior management, ensuring accountability to the board. The committee’s structure and operational guidelines are designed to align with relevant Chinese laws and Hong Kong securities regulations, aiming to improve decision-making processes and maintain high standards of governance.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has established a Nomination Committee to enhance its corporate governance by optimizing the selection process for directors and senior management. The committee, comprising mainly independent non-executive directors, is tasked with advising on the criteria and procedures for selecting board members and senior executives, thereby ensuring a diverse and skilled board composition aligned with the company’s strategic goals.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has established a Strategy Committee within its board of directors to enhance decision-making and governance. The committee is tasked with researching and advising on the company’s long-term development strategies and significant investment decisions, reflecting a strategic move to strengthen oversight and optimize management processes.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has established an Audit Committee to enhance its governance structure and ensure effective oversight of its management team. The committee, composed primarily of independent non-executive directors, is tasked with supervising the company’s internal control, financial information, and internal audit processes. This move is expected to strengthen the company’s governance and provide reassurance to stakeholders about the integrity of its financial and operational practices.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced proposed amendments to its Articles of Association and Rules of Procedures to comply with recent changes in Chinese Company Law and the Hong Kong Stock Exchange’s paperless listing regime. The amendments include the abolishment of the supervisory committee, with its functions transferred to the audit committee, aligning with regulatory requirements for electronic corporate communications. These changes are subject to shareholder approval at an upcoming extraordinary general meeting.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. held an adjourned H Shareholders’ Class Meeting on December 3, 2025, in Beijing. The meeting, which was chaired by Ms. Shi Wenling, complied with PRC laws and Hong Kong Stock Exchange listing rules. All directors attended, with some participating via telephone. The meeting involved a registered poll for voting, with no restrictions or abstentions noted among shareholders.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced a cash dividend for the third quarter of 2025, with shareholders approving a dividend of RMB 2.1 per 10 shares. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09716, with a payment date set for January 19, 2026. The announcement also detailed withholding tax rates applicable to different categories of shareholders, impacting non-resident enterprises and individuals, as well as mainland investors through stock connect programs.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. successfully held its Extraordinary General Meeting (EGM) and A Shareholders’ Class Meeting on November 19, 2025, in compliance with relevant laws and regulations. All proposed resolutions were passed without opposition, and the meetings were attended by all directors, either in person or by telephone, indicating strong governance and shareholder engagement.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the adjournment of its H Shareholders’ Class Meeting due to insufficient voting rights representation. The meeting, originally scheduled for November 19, 2025, will now be held on December 3, 2025. The company has ensured that previously submitted proxy forms remain valid for the rescheduled meeting, maintaining continuity for shareholders.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced the subscription of structured deposit products with various branches of the Bank of Beijing and Shanghai Pudong Development Bank, amounting to significant investments using both internal resources and temporary idle proceeds from public issuance of A shares. These transactions, which exceed 5% but are below 25% of applicable percentage ratios, are classified as discloseable transactions under the Listing Rules, requiring reporting and announcement but exempt from shareholder approval.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced an extraordinary general meeting scheduled for November 19, 2025, to discuss significant changes in its governance structure. The meeting will consider the abolishment of the Supervisory Committee, amendments to the Articles of Association, and changes to the rules of procedures for general and board meetings. Additionally, amendments to the working system for independent directors and management measures for the use of proceeds will be reviewed, along with the 2025 Third Quarterly Profit Distribution Plan. These proposed changes indicate a strategic shift in the company’s governance and operational procedures, potentially impacting its stakeholders and market positioning.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for its H shareholders to discuss and potentially approve significant changes, including the abolishment of the Supervisory Committee and amendments to the Articles of Association and procedural rules for meetings. These changes could streamline the company’s governance structure, potentially impacting its operational efficiency and strategic decision-making processes.
The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.